Park Compounding Pharmacy (Chen Shwezin, Inc.), Westlake Village, CA
Is Park Compounding Pharmacy (Chen Shwezin, Inc.) registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Park Compounding Pharmacy (Chen Shwezin, Inc.) hold a California pharmacy license?
The California State Board of Pharmacy lists license PHY 54304 for Park Compounding Pharmacy, Westlake Village, status Active, as of Nov 6, 2026. The Texas State Board of Pharmacy also lists nonresident license 34305 for PARK COMPOUNDING PHARMACY, WESTLAKE VILLAGE, CA, status Active, as of Nov 15, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 7672 for PARK COMPOUNDING PHARMACY, Westlake Village, CA, status Active, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054022235 for CHEN SHWEZIN, INC, WESTLAKE VILLAGE, CA, status ACTIVE, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0004078 for PARK COMPOUNDING PHARMACY, WESTLAKE VILLAGE, CA, status ACTIVE (CURRENT), as of Nov 15, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012956 for Chen Shwezin, Inc., Westlake Village, CA, status Active, as of Nov 10, 2026.
Has Park Compounding Pharmacy (Chen Shwezin, Inc.) had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jul 20, 2020), 1 state referral letter (Jul 20, 2020) and 1 FMD-145 letter (Jul 20, 2020) for Park Compounding Pharmacy (Chen Shwezin, Inc.). State board actions: no California State Board of Pharmacy action on license PHY 54304 or under this exact name and city was found in the board’s posted disciplinary decisions on facility licenses (actions dated Jan 5, 2005 to Oct 28, 2026) on Nov 6, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Chen Shwezin, Inc.; Park Compounding Pharmacy
- Location
- Westlake Village, CA
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Jul 20, 2020
- FDA Data Dashboard inspections
- 1 inspection: 1 OAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 5 observations
- State board records
- License found: PHY 54304, Active
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Chen Shwezin, Inc., (dba Park Compounding Pharmacy), a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Jul 20, 2020 | FMD-145 letter | FMD-145 Letter Issued 07/20/2020 | FDA copy (archived) |
| Jul 20, 2020 | Warning letter close-out | Warning Letter Closeout Issued 07/20/2020 | Not linked by FDA |
| Jul 20, 2020 | State referral letter | Referral Letter to the California State Board of Pharmacy Issued 07/20/2020 | FDA copy (archived) |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Chen Shwezin, Inc., Westlake Village, CA (FEI number 3005256616), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 11, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3005256616 | 942326 |
Form 483s FDA has published for this site
- Apr 16, 2018: Form 483 to Chen Shwezin, Inc., published Jan 17, 2024. fda.gov
- Oct 5, 2015: Form 483 to Chen Shwezin, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 5 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Mar 26, 2018 to Apr 3, 2018: 5 observations
- Firm on the cover
- Chen Shwezin DBA Park Compounding Pharmacy, 4333 Park Terrace Drive, #160, Westlake Village, CA 91361
- FEI number
- 3005256616
- Establishment type on the cover
- producer of non-sterile drug products
- FDA district office on the cover
- Not read
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.
Specifically, your firm conducted potency testing on three finished drug products during the previous eight months which were supposed to represent all distributed products and dosage forms. Product selection did not consider factors such as difficulty to produce or the relative amount of active ingredient. Examples of drug products distributed without adequate assurance they met their labeled strength claims include: - Lidocaine + Tetracaine 23+7% cream, 60 mL, lot 02072018@12 - Diclofenac suppository, 100 mg, lot 01042018@13 -Trichloroacetic Acid 35% solution, 60 mL, lot 03142018@16 - Cantharidin Plus liquid, 100 mg/10 mL, lot 01192018@13 - Benzocaine + Lidocaine + Tetracaine 20+8+4% Lipoderm, 30 gm, lot 03132010@32
Observation 2
Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent malfunctions and contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Specifically, there were no written cleaning, sanitization, or maintenance procedures. I observed equipment designated clean was soiled. There was no documented evidence cleaning agents effectively removed drug products residues, and that cleaning agents were completely removed.
A) Capsule plates designated clean and ready for production use contained powder residue on the inner edges of the slots which directly contact open capsules during filling. There was visible, loose powder on the upper work surfaces and outer housing ofthree·o£Cb)C4Y· capsule machines.
B) I observed an apparent hair stuck to residue on one roller of an <Redacte d B4> ointment mill which was designa ted clean and ready for production use.
C) 5 oz <Redacted B4> spatulas used to transfer finished drug products into their final container closure had several sections missing from the bottom edge which created a rough, uneven surface. ...
Observation 3
Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established, written, and followed.
Specifically, the tool used to <Redacted B4> compress powder into capsules was cleaned, sanitized, and then stored o n a soiled, wet cloth for approximately <Redacted B4> hours. The tool was upright on the protrusions which directly contact powder inside the capsules.
Observation 4
Each lot of a component that is liable to microbiological contamination that is objectionable in view of its intended use is not subjected to microbiologieal tests before use.
Specifically, your firm did not perform microbiological or ionic testing to ensure water quality met applicable standards for non-sterile drug production. Production personnel used
<Redacted B4> Water to produce water based suspensions. Water for drug production was supplied in <Re dacted B4> and dispensed from a water cooler in the employee break room. I observed employees fill their personal wate r bottles using the same water cooler. <Redacted B4> was used to produce Trichloroacetic Acid 35% solution, 60 mL, lot 03142018@16.
Observation 5
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, sampling plans, and test procedures designed to assure drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, your firm did not establish specifications for acceptable levels of microorganisms or conduct microbial enumeration tests for non-sterile drug products. Examples of drug products distributed without microbial enumeration information include: - Lidocaine + Tetracaine 23+7% cream, 60 mL, lot 02072018@12 - Diclofenac suppository, 100 mg, lot 01042018@13 -Trichloroacetic Acid 35% solution, 60 mL, lot 03142018@16 - Cantharidin Plus liquid, l 00 mg/1 0 ml, lot 01192018@13 - Benzocaine + Lidocairte + Tetracaine 20+8+4% Lipoderm, 30 gm, lot 03132010@32
Linked 483s whose text is not shown
- Oct 5, 2015: FDA document 93914: its numbered observations could not be read reliably from the PDF text.
State board of pharmacy records
The California State Board of Pharmacy file dated Nov 6, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PHY 54304 | Retail Pharmacy | Park Compounding Pharmacy | Westlake Village | Active |
What this covers: Facility license decisions from the board’s quarterly Disciplinary Actions pages (87 of 88 quarters had a facility section). These are final decisions; accusations filed and immediate protection orders are not included. Actions in the data are dated Jan 5, 2005 to Oct 28, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Texas State Board of Pharmacy, file dated Nov 15, 2026 (Texas).
| License | Type as the board gives it | Name on the board record | Location | Status | Prior disciplinary orders (file flag) |
|---|---|---|---|---|---|
| 34305 | Non-Resident (Not Located in Texas) | PARK COMPOUNDING PHARMACY | WESTLAKE VILLAGE, CA | Active | No |
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 7672 | OSP | PARK COMPOUNDING PHARMACY | Westlake Village, CA | Active |
Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 054022235 | LICENSED PHARMACY | CHEN SHWEZIN, INC | WESTLAKE VILLAGE, CA | ACTIVE |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0004078 | NONRESIDENT PHARMACY | PARK COMPOUNDING PHARMACY | WESTLAKE VILLAGE, CA | ACTIVE (CURRENT) |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301012956 | Pharmacy | Chen Shwezin, Inc. | Westlake Village, CA | Active |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- California State Board of Pharmacy license file
- Texas State Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Illinois Department of Financial and Professional Regulation license file
- Connecticut Department of Consumer Protection license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Texas State Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.